Enhancing Alzheimer's research with technology advancements
In collaboration with Amazon Web Services (AWS) and Datavant, Labcorp has launched a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster.
The platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate scientific discovery, shorten drug development timelines and improve identification of patients for clinical trial recruitment. The platform enables researchers, biopharma companies, payors and contract research organizations to generate insights in minutes that previously required months of intensive data mining.
Labcorp's platform leverages standardized, direct-from-source laboratory data captured across millions of patients and advanced AI models to streamline data access and analysis. It combines Labcorp's extensive diagnostic and genomic datasets with medical claims, and, in future versions, electronic health record and social determinants of health data. Powered by advanced AI analytics, the platform can quickly identify patient cohorts, track disease progression patterns and measure treatment effectiveness across diverse populations.
The platform's AI-powered analytics interface offers:
- Real-time, population-level analysis of treatment patterns, effectiveness and patient outcomes across diverse populations
- Characterization of patient segments tested for Alzheimer's disease
- Support for the selection of deidentified patient cohorts suitable for clinical trial recruitment based on defined inclusion and exclusion criteria
- Advanced statistical modeling tools to identify patient cohorts with unmet clinical need
The platform will complete its initial validation phase in spring 2026 and is expected to expand through 2026, incorporating additional data sources and analytical capabilities to further accelerate research insights including inflammatory diseases, cardiometabolic conditions, women's health and oncology.
